Macroglobulinemic Waldenström's purpura

Waldenström's macroglobulinemia purpurea (WMP) is a rare blood disorder characterized by excessive production of antibodies to macroglobulins (proteins that link immune system cells to other cells). These antibodies can cause damage and destruction of red blood cells, leading to anemia and other symptoms.

PMHV was first described in 1937 by Waldenström. He found that some patients with lymphoma (cancer of the lymphatic system) had increased production of macroglobulin antibodies. It was later established that PMH is an independent disease, and not just one of the manifestations of lymphoma.

PMH usually occurs in people between 40 and 60 years of age, although it can occur in children. Symptoms may include fatigue, weakness, decreased appetite, weight loss, bone and joint pain, bleeding from the nose and gums, and changes in blood tests such as anemia, thrombocytopenia, and leukopenia.

Diagnosis of PMGV includes a blood test for the level of macroglobulins and antibodies to them, as well as a bone marrow biopsy to determine the presence of a tumor. Treatment usually includes chemotherapy and/or bone marrow transplantation. However, some patients can achieve remission without treatment, making PMH an unpredictable disease.

Overall, Waldenström's macroglobulinemia purpurea is a rare and serious blood disorder. Although the exact cause of PMHV is unknown, research suggests that it may be due to genetic mutations or a disorder of the immune system. Patients with PMH require regular medical follow-up and treatment to control symptoms and prolong life.